New radioactive drug targets tough prostate cancer in early trial
NCT ID NCT07381582
First seen Feb 02, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This early-phase study tests a new radioactive drug, 161Tb-LNC1011, in 15 men with advanced prostate cancer that no longer responds to hormone therapy. The drug is designed to seek out and deliver radiation directly to cancer cells. The main goals are to check safety, find the best dose, and see if it can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Mianyang Central Hospital
Mianyang, Sichuan, China
Contact Phone: •••-•••-••••
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.